Answers are grounded in this paper and cite their sources.
The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Kevin M. Wright (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: